Please assess the completion status of the following clinical trial:

Trial Title: Glucocorticoid Antagonist Treatment for Tobacco Use Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male smokers aged 18 to 55 years;~* History of smoking at least 5 cigarettes daily for the past 12 months;~* In good health as verified by medical history, screening examination, and -screening laboratory tests~Exclusion Criteria:~* History of mifepristone allergy;~* Requirement of any form of regular psychotropic medication (antidepressants, antipsychotics, or anxiolytics) and recent psychiatric history (in the past 6 months);~* Medical illnesses including diabetes, cardiovascular, renal, endocrine, or hepatic disorders;~* Prolonged QTc interval \>450 msec;~* History of adrenal insufficiency or a morning plasma cortisol level less than 5 mcg/dl at screening;~* Hypokalemia at screening (defined as potassium level \< 3.5 mEq/L);~* Current use of clinically significant CYP 3A4 substrates including, simvastatin, lovastatin, cyclosporine, ergotamines, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, triazolam, midazolam.~* use of rifapentin, phenobarbital, phenytoin, carbamazepine, and St. John's Wort.~* Current use of strong 3A4 inhibitors including ketoconazole, itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir, fosamprenivir, boceprevir, clarithromycin, conivaptan, lopinavir, mibefradil, posaconazole, saquinavir, telaprevir, telithromycin, voriconazole.~* Treatment with systemic corticosteroids~* Current use of clinically significant CYP 3A inducers (e.g., rifampin, rifabutin);~* Abuse of alcohol or any other illicit or prescription drugs;~* Inability to tolerate cold exposure due to conditions such as peripheral -vascular disease or Raynaud's phenomenon;~* Inability to fulfill all scheduled visits and examination procedures throughout the study period.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Mifepristone (Type: ACTIVE_COMPARATOR): Mifepristone 600 mg/day in 2 tablets
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo in 2 tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).